Randomized controlled trial to evaluate an app-based multimodal digital intervention for people with type 2 diabetes in comparison to a placebo app.

ABSTRACT:

Introduction

This multi-center, parallel-group randomized controlled trial evaluated the app-based intervention mebix, developed by Vision2b GmbH in Germany, for people with type 2 diabetes compared to a placebo app.

Method

A total of 153 participants were randomized in a 1:1 ratio to either intervention or control group, with allocation concealment ensured by a minimization procedure.

Results

After six months, participants using mebix achieved a statistically significant reduction in HbA1c levels by 0.82 percentage points (95% confidence interval: -1.20, -0.48, p = 0.003). This reduction was greater than in the control group (mean difference: 0.24 percentage points, 95% confidence interval: -0.44, 0.09). mebix users further experienced gre

SUBMITTER: Roth L 

PROVIDER: S-EPMC12738949 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature